The study evaluated patients with chronic myelogenous leukemia, Philadelphia chromosome-positive acute lymphocytic leukemia and myeloproliferative disorders, or MPD, a group of blood diseases that can develop into leukemia.
The company now plans to commence its previously-announced phase IIa clinical trial for MEM 3454 in Alzheimer's disease during the first quarter of 2007. The FDA had originally
The companies also said that a phase III trial in catheter occlusion did not meet the endpoint of restoration of function at 15 minutes. These trials did not
The primary objective was to answer whether the Xelox (oral Xeloda plus oxaliplatin) regimen is as effective as Folfox-4 (infused 5-FU/leucovorin plus oxaliplatin) in delaying disease progression or
The objectives of the studies were to determine the safety and tolerability of DUR-843 in healthy human volunteers as well as evaluate the pharmacokinetics of the active pharmaceutical
Results are from the first stage of an ongoing phase III study of HuMax-CD4 in cutaneous T-cell lymphoma (CTCL) and an ongoing phase II study in non-cutaneous T-cell
Chemotherapy plus Biogen Idec's Rituxan is the emerging standard of care for this patient population. When added to the chemotherapy/Rituxan combination regimen, lumiliximab demonstrated a 52% complete response
Idraparinux is being developed as an alternative to standard treatment heparin, and can be taken less often than current medication. The researchers' primary measure of success was whether
Ceflatonin is for use in chronic myeloid leukaemia (CML) patients who have developed resistance to Gleevec and other tyrosine kinase inhibitors. Following treatment with the drug combination, 42%
Graft vs host disease, or GVHD, is a life threatening immunological reaction that occurs in certain patients who have received a bone marrow transplant. There are no approved
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.